Clinical Trial Detail

NCT ID NCT02655822
Title Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Corvus Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

renal cell carcinoma

lung non-small cell carcinoma

melanoma

colorectal cancer

prostate cancer

urinary bladder cancer

Therapies

Atezolizumab + CPI-444

CPI-444

Age Groups: senior adult

Additional content available in CKB BOOST